ArticleBMC pulmonary medicine2025

A phase I trial of combination CAR-NK92MI immunotherapy by dual targeting MUC-1 and PD-L1 for patients with relapsed or refractory solid tumors: focus on non-small cell lung cancer.

Jing Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.